Investment Terms
Funding Target $2,500,000
Round Series A
Pre-Money Valuation $39,000,000
Sector Healthcare Technology
to Invest


EntelMed’s strategy is to become a leading national provider of comprehensive technology-enabled healthcare through the merger and acquisition of multiple artificial intelligence (“AI”), automation, data science, and Software-as-a-Service (“SaaS”) companies each valued at between $50 million to $500 million. The Company’s strategy is to use institutional private capital to complete up to five acquisitions and follow the initial acquisitions with an initial public offering.

EntelMed has identified potential business combination targets, and is engaged in substantive discussions, directly or indirectly, with potential business combination targets.

EntelMed believes that the technology-enabled healthcare services industry presents an attractive set of opportunities for consolidation. Specifically, the industry is highly fragmented and demands specialization to access attractive companies. Many of these companies exhibit attractive financial profiles and are capable of serving as platform companies.

Key Highlights

  1. Digitization is revolutionizing healthcare. Telemedicine, Artificial Intelligence (AI), connected wearables, 5G mobile technology, Blockchain electronic health records, digital therapies, remote patient monitoring, automated billing and insurance claims, and virtual chatbots. The global market could reach $524 billion by 2025.
  2. Digital healthcare is creating a new paradigm where administrative work and physician processes are streamlined, systems are optimized, experiences and outcomes are improved, human errors are eliminated and overall costs for patients and healthcare organizations are significantly reduced.
  3. Buy and Build Strategy. Rather than building EntelMed from scratch using expensive R&D, the strategy is to acquire technology enabled healthcare companies with existing technology, a customer base and significant growth potential and combine them to create a large revenue producing enterprise.
  4. EntelMed’s strategy is to use a programmatic merger and acquisition strategy to acquire and combine multiple companies in order to rapidly build value and qualify the company for an IPO.

The Team

Joe Barr, PhD.

Joseph Barr, Ph.D. is the Chief Technology Officer of EntelMed, Inc. Since 2017, Mr. Barr has served as the Chief Data Scientist and Managing Director of Barr Analytics LLC, where he engages…

Fabio Persia, PhD.

Fabio Persia, Ph.D. is a Scientist at EntelMed, Inc. Since 2015, Mr. Persia has been an Assistant Professor of Computer Science at the Free University of Bozen-Bolzano (Italy). Mr. Persia is…

Peter Shaw, PhD.

Peter Shaw, PhD. Professor of Artificial Intelligence at Nanjing University, Former Senior Lecturer at Massey University, Former Senior Lecturer at Charles Darwin University, PhD. in…

Daniella , PhD.

Daniella D’Auria, PhD. is a Scientist at EntelMed, Inc. Since 2020, Ms. D’Auria has been an Assistant Professor of Medical Devices and Robotics at Free University of Bozen-Bolzano (Italy)…

Join or sign in to view EntelMed’s team.

Create Your Investment Account Today

Access Deal Documents, Financial Projections, and Invest Directly in Exclusive Opportunities.

Create Account